The UK left the EU at 11pm on 31 January 2020. What does this mean for the regulation of medicines and medical devices, in particular their authorisation? This note explains the effect of the transition period on EU law and the special arrangements provided in the Withdrawal Agreement relating to life sciences products.

This content is restricted to members. To view this content please register or login below to view this content.

Register to receive up-to-date information and advice on tax developments within your industry.